You can also read the IBTA e-News November 2019 edition in full online here.
Some of the highlights from this month's round-up:
- The 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology took place in Phoenix, Arizona, USA. This year’s conference theme was “Innovation to Overcome Tumor Resistance”. The IBTA is very excited and honoured to announce that its Chair and Co-Director Kathy Oliver received SNO’s Neuro-Oncology Community Service Award which was presented to her in Phoenix on the opening day of the conference.
- The latest paper from the EORTC SISAQOL initiative is now available as a pre-print. This paper provides consensus recommendations based on literature review and input from an international multi-expert, multi-stakeholder consortium of which the IBTA is a member.
- Researchers believe they have identified a protein, called CEMIP, that various cancers produce to help them spread to the brain. These findings suggest that in future work, CEMIP could be targeted to predict, prevent and treat brain metastases.
- According to a study published in the journal Neuro-Oncology Practice, survival rates from one of the most common forms of brain tumour have risen sharply after surgical advances prompted a shift in how these tumours are treated.
- A multicentre study has charted the natural progress of spinal ependymoma in adults. This is a rare tumour type, which has to date received limited research attention. The authors’ conclusions recommend that gross-total resection of the tumour has an important impact on prognosis.
- A blood test measuring ‘plasma cell-free DNA’ could be an effective biomarker for assessing brain tumour burden and may be a viable prognostic measure for disease progression in patients with newly-diagnosed glioblastoma.
- The largest-ever time series database of glioma genetic profiles has been published in the journal Nature. The research found that brain tumours treated with radiation or chemotherapy evolve in a way that appears to be random, explaining why gliomas are so difficult to treat.
- Biopharmaceutical company Oncoceutics has announced a publication in the journal Nature Communications demonstrating that the company’s lead candidate drug imipridone selectively binds to and antagonises the G-protein coupled receptor, dopamine receptor D2.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.